Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 56 citing articles:

H3K18 lactylation promotes the progression of arsenite-related idiopathic pulmonary fibrosis via YTHDF1/m6A/NREP
Peiwen Wang, Daxiao Xie, Tian Xiao, et al.
Journal of Hazardous Materials (2023) Vol. 461, pp. 132582-132582
Closed Access | Times Cited: 56
Nanoengineered mesenchymal stem cell therapy for pulmonary fibrosis in young and aged mice
Meng‐Meng Han, Xing-Yue He, Tang Ling, et al.
Science Advances (2023) Vol. 9, Iss. 29
Open Access | Times Cited: 39
Lipid metabolism in idiopathic pulmonary fibrosis: From pathogenesis to therapy
Ranxun Chen, Jinghong Dai
Journal of Molecular Medicine (2023) Vol. 101, Iss. 8, pp. 905-915
Closed Access | Times Cited: 27
Pulmonary inflammation and fibroblast immunoregulation: from bench to bedside
Mohamed A. Ghonim, David F. Boyd, Tim Flerlage, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 17
Open Access | Times Cited: 24
Lactate facilitated mitochondrial fission-derived ROS to promote pulmonary fibrosis via ERK/DRP-1 signaling
Zhiheng Sun, Zhihua Ji, Huiwen Meng, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 10
Respiratory diseases and gut microbiota: relevance, pathogenesis, and treatment
Mengdi Sun, Fang Lü, Donghua Yu, et al.
Frontiers in Microbiology (2024) Vol. 15
Open Access | Times Cited: 9
Phillygenin Inhibits PI3K‐Akt–mTOR Signalling Pathway to Prevent bleomycin‐Induced Idiopathic Pulmonary Fibrosis in Mice
Yongjia Wei, Wenting Ni, Lizhi Zhao, et al.
Clinical and Experimental Pharmacology and Physiology (2025) Vol. 52, Iss. 2
Closed Access | Times Cited: 1
Advances in cellular senescence in idiopathic pulmonary fibrosis (Review)
Shan Han, Qiangwei Lu, Xiaoqiu Liu
Experimental and Therapeutic Medicine (2023) Vol. 25, Iss. 4
Open Access | Times Cited: 17
HSP47: A Therapeutic Target in Pulmonary Fibrosis
Noriho Sakamoto, Daisuke Okuno, Takatomo Tokito, et al.
Biomedicines (2023) Vol. 11, Iss. 9, pp. 2387-2387
Open Access | Times Cited: 17
Modelling bronchial epithelial-fibroblast cross-talk in idiopathic pulmonary fibrosis (IPF) using a human-derived in vitro air liquid interface (ALI) culture
Sarah L. Barron, Owen Wyatt, Andy J. O'Connor, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Role of cellular senescence in inflammatory lung diseases
Cong Xie, Mai Maititusun Ya Likun, Qingli Luo, et al.
Cytokine & Growth Factor Reviews (2023) Vol. 70, pp. 26-40
Closed Access | Times Cited: 12
Chinese medicine as a therapeutic option for pulmonary fibrosis: Clinical efficacies and underlying mechanisms
Yanwei Hao, Jiaxin Li, Lijuan Dan, et al.
Journal of Ethnopharmacology (2023) Vol. 318, pp. 116836-116836
Closed Access | Times Cited: 11
Cell therapy: A beacon of hope in the battle against pulmonary fibrosis
Ruyan Wan, Yanli Liu, Jingwen Yan, et al.
The FASEB Journal (2025) Vol. 39, Iss. 2
Closed Access
Ameliorative effects of avocado oil on bleomycin‐induced lung fibrosis and oxidative stress in rats
Naoures Ochi, Anouar Abidi, Wael Taamalli, et al.
Physiological Reports (2025) Vol. 13, Iss. 3
Open Access
FBR2 modulates ferroptosis via the SIRT3/p53 pathway to ameliorate pulmonary fibrosis
Yu Cheng, Yang Jiao, Wan Wei, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
The Intersection between Immune System and Idiopathic Pulmonary Fibrosis—A Concise Review
Hongli Liu, Huachun Cui, Gang Liu
Deleted Journal (2025) Vol. 3, Iss. 1, pp. 10004-10004
Closed Access
Targeting endothelial cells: A novel strategy for pulmonary fibrosis treatment
Xin Zhang, Yuxia Sha, Yu‐Wei Wu, et al.
European Journal of Pharmacology (2025), pp. 177472-177472
Closed Access
Effective-compounds of Jinshui Huanxian formula acts as an SRC inhibitor to inhibit HK2-mediated H3K18 lactation and improve pulmonary fibrosis.
Jiaping Zheng, Yan Du, Wenbo Shao, et al.
Phytomedicine (2025) Vol. 140, pp. 156628-156628
Closed Access
Apigenin as a multifaceted antifibrotic agent: therapeutic potential across organ systems
Xiaoyong Hu, D.J.A.N.D.A.N.T.A.D.U.M. ARTHUR VITHRAN, Zhaoying Yang, et al.
Journal of Agriculture and Food Research (2025), pp. 101816-101816
Open Access
Bioinformatics-based identification of mirdametinib as a potential therapeutic target for idiopathic pulmonary fibrosis associated with endoplasmic reticulum stress
Junwei Chen, Y. W. Du, Qi Yu, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
The dual antioxidant chitosan oligosaccharides regulate the transdifferentiation of lung effector cells in the management of idiopathic pulmonary fibrosis
Huan He, Youtao Xu, Xinru Chen, et al.
Carbohydrate Polymer Technologies and Applications (2025), pp. 100782-100782
Open Access
Targeted Drug Delivery System for Pulmonary Fibrosis: Design and Development of Biomaterials
Jinsha Liu, Zifeng Pan, Aatif Khan, et al.
BIO Integration (2025) Vol. 6, Iss. 1
Open Access
Theophylline Attenuates BLM-Induced Pulmonary Fibrosis by Inhibiting Th17 Differentiation
Soo-Jin Park, Hwa-Jeong Hahn, Sei‐Ryang Oh, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1019-1019
Open Access | Times Cited: 10
Eliglustat exerts anti-fibrotic effects by activating SREBP2 in TGF-β1-treated myofibroblasts derived from patients with idiopathic pulmonary fibrosis
Eon Kurumiya, Mayuu Iwata, Yoshitoshi Kasuya, et al.
European Journal of Pharmacology (2024) Vol. 966, pp. 176366-176366
Closed Access | Times Cited: 3
Dysregulated bidirectional epithelial–mesenchymal crosstalk: A core determinant of lung fibrosis progression
Liudi Yao, Zijian Xu, Donna E. Davies, et al.
Chinese Medical Journal - Pulmonary and Critical Care Medicine (2024) Vol. 2, Iss. 1, pp. 27-33
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top